Profile (Overview)
The Princess Margaret Cancer Centre, formerly known as Princess Margaret Hospital, is a medical research facility and teaching hospital located in Toronto, Ontario, Canada. It is a member of the University Health Network and is associated with the University of Toronto Faculty of Medicine. The hospital is currently one of the top five cancer centres in the world and Canada's largest cancer centre. It constitutes one of the largest clusters of cancer hospitals in the world along with the Odette Cancer Centre, which is also related to the University of Toronto School of Medicine and is separately the sixth largest cancer centre in North America. In 1952, an Act of the Ontario government established the hospital as the Ontario Cancer Institute. It was initially situated next to the former Wellesley Hospital at 500 Sherbourne Street, which is now a condominium complex, and was designed by architect Henry Sproatt. The Toronto Hospital, the organisation created by the previous merger of the Toronto General Hospital and the Toronto Western Hospital, and Princess Margaret Hospital merged during the health restructuring legislation passed by the Harris Government in the late 1990s. The new combined organisation was named University Health Network (UHN), with the three distinct hospitals maintaining their own identities within the new hospital corporation. The hospital primarily serves people living in the Greater Toronto Area and specialises in the treatment of cancer. The hospital has specialists in the departments of radiation therapy, medical imaging, surgical oncology, medical oncology, haematology, including bone marrow transplantation, radiation oncology, psychosocial oncology, and haematology.
Hospital (Infrastructure)
Hospital Location
Facilities
Hospital Awards
Available Specialities
Popular Procedures
DOCTORS
The Universidad del Salvador in Buenos Aires, Argentina, is where Dr. Diego Delgado received his medical degree. In Hospital Espanol in Buenos Aires, he finished his training in internal medicine and cardiology. At Rush Presbyterian St Luke's Medical Center in Chicago, Illinois, he later finished a research fellowship in heart transplantation. In the Toronto General Hospital, he did a research and clinical residency in heart failure and transplantation. At the University of Toronto and the Rotman School of Management in Toronto, Dr. Delgado earned his Masters of Science in clinical epidemiology. The Reuben and Florence Fenwick Family Chair in the Medical Treatment of Heart Failure is held by Dr. Delgado. Dr. Delgado is a member of the University's Heart Failure, Transplantation and Mechanical Assist Device Program and a transplant cardiologist. View Profile
Eitan Amir, MD, is an associate professor in the University of Toronto's Department of Medicine and a medical oncologist at the Princess Margaret Cancer Centre in Toronto. He is the Site Head for Breast Medical Oncology and the Executive Director of the Princess Margaret Cancer Centre's Medical Oncology and Hematology Fellowship programme. Also, he is the Vice-Chair of the Cancer Research Ethics Board at University Health Network as well as the Systemic Treatment Lead for Toronto Central South for Cancer Care Ontario. Treatment of breast cancer and the side effects of anti-cancer medications are two of Dr. Amir's clinical specialties. His scholarly interests include meta-analysis, outcomes research, and clinical trial methods. At the University of Manchester in the UK, Dr. Amir earned his medical degree and received training in internal medicine and medical oncology. At the University of Toronto, he later earned a Doctorate in clinical epidemiology. Dr. Amir has authored more than 250 books, book chapters, and abstracts that have been published. View Profile
Professor of Surgery at the University of Toronto is Dr. Gelareh Zadeh. She works for the University Health Network's Toronto Western Hospital as a neurosurgeon-scientist. Most recently, the Wilkins Family Chair in Brain Tumor Research was given to her. Her clinical practise is focused on Skull Base Neuro-oncology, and she has established and is actively involved in numerous multidisciplinary clinics, including the skull base, pituitary, brain metastases, gamma knife, and neurofibromatosis clinics. She also has a dedicated general brain tumour clinic. She is committed to and actively participating in the effort to advance surgical clinical trials. Her lab's primary areas of study include the molecular mechanisms underlying glioma angiogenesis and the metabolic regulators of tumours. examining in particular how cells from the bone marrow help gliomas' tumour vasculature and how differentiation into the macrophage and microglia populations contributes to avoiding anti-angiogenic therapy. The laboratory's second area of study, tumour metabolism, looks at how altered metabolism in response to anti-angiogenic therapy interacts with one another. She also has a translational study that is focused on mapping the menignomas and schwannomas' genomic landscape. Peer-reviewed funding from several organisations, including the CIHR, Terry Fox New Investigator grant, CCSRI, CRS, Brain Child, and others, are used to fund her lab. View Profile
Dr. Tony Finelli is a full professor at the University of Toronto as well as an investigator and urologic oncologist at the University Health Network (UHN) in Toronto. He is the Princess Margaret Cancer Center's GU Site Lead, Chief of Urology, and Ontario's first-ever GU Oncology Lead (Cancer Care Ontario). Dr. Finelli performs urologic oncology health services research with the goal of identifying treatment gaps and developing knowledge translation strategies to close them. Also, he actively participates in clinical trials. He has received peer-reviewed funding for research on prostate and kidney cancer and has produced more than 100 peer-reviewed articles. The therapy of urologic cancers with minimally invasive and robotic procedures is the main emphasis of Dr. Finelli's clinical practise. For educational purposes, he has carried out real surgery in more than ten different nations. With his contributions to minimally invasive urologic oncology, Dr. Finelli has received both national and international recognition. View Profile
Dr. Bernardini is an Associate Professor in the Department of Obstetrics and Gynecology at the University of Toronto, the Division Head of Gynecologic Oncology at the University Health Network, and an Associate Scientist at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital. Dr. Bernardini, a graduate of the University of Western Ontario, then pursued a combined fellowship in gynecologic oncology at the University of Toronto and Duke University Medical Center after completing his residency and earning a master's degree in laboratory and pathobiology at the University of Toronto. Associate professor at the University of Toronto, Dr. Bernardini has won honours for both teaching and research, including the 2014 ""Award for Teaching Excellence"" and the 2018 ""Senior Merit Award"" (research). View Profile
Dr. Bernardini is an Associate Professor in the Department of Obstetrics and Gynecology at the University of Toronto, the Division Head of Gynecologic Oncology at the University Health Network, and an Associate Scientist at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital. Dr. Bernardini, a graduate of the University of Western Ontario, then pursued a combined fellowship in gynecologic oncology at the University of Toronto and Duke University Medical Center after completing his residency and earning a master's degree in laboratory and pathobiology at the University of Toronto. Associate professor at the University of Toronto, Dr. Bernardini has won honours for both teaching and research, including the 2014 ""Award for Teaching Excellence"" and the 2018 ""Senior Merit Award"" (research). He is the co-director of the Women's College Prevent Ovarian Cancer Program and heads the UHN robotic surgery programme. Understanding the function of precursor lesions in high grade serous ovarian cancer and cytoreductive surgery for later stage illness are among his research interests. He is the Lead Investigator of the Early Stage Cohort for the CANSTAMP trial investigating new approaches to front-line therapy in serous and/or p53 abnormal/mutant endometrial cancer, and he co-leads the ovarian cytoreductive programme as well as CANSTIC, a pan-Canadian study looking at treatment and outcomes of ovarian pre-cursor lesions. View Profile
